Albendazole and Praziquantel: Review and Safety Monitoring in Korea
1
조회
0
다운로드
3
인용
0
참고문헌
키워드
초록
Albendazole (ADZ) and praziquantel (PZQT) have been used as anthelmintics for over 30 years. Worldwide, hundreds of millions tablets are administered to people and livestock every year. ADZ is poorly orally absorbed (<5%), and its uptake is enhanced by high-fat meals, while PZQT is well absorbed (>75%) and uptake is enhanced by carbohydrate-rich meals. Both ADZ and PZQT are safe, but not recommended for children <2 years or for women in the first trimester of pregnancy. Serious adverse events occur following high dose and prolonged administration of these drugs for treatment of echinococcosis or neurocysticercosis, especially in patients with poor liver function. The adverse events may be induced by the drugs, or by the dead worms themselves. The Korea Institute of Drug Safety & Risk Management monitors drug-related adverse events in Korea, and its database included 256 probable or possible ADZ-associated events and 108 PZQT-associated events between 2006 and 2015. Such low incidence rates in Korea are due to the low single dose treatments of ADZ, and the short-term use of PZQT. The number of serious adverse events due to drug interaction induced by ADZ and PZQT were six and two, respectively. We conclude that ADZ and PZQT are generally safe drugs, but they must be used with caution in people with poor liver function or those being comedicated for gastroesophageal reflux disease.
Abstract
Albendazole (ADZ) and praziquantel (PZQT) have been used as anthelmintics for over 30 years. Worldwide, hundreds of millions tablets are administered to people and livestock every year. ADZ is poorly orally absorbed (<5%), and its uptake is enhanced by high-fat meals, while PZQT is well absorbed (>75%) and uptake is enhanced by carbohydrate-rich meals. Both ADZ and PZQT are safe, but not recommended for children <2 years or for women in the first trimester of pregnancy. Serious adverse events occur following high dose and prolonged administration of these drugs for treatment of echinococcosis or neurocysticercosis, especially in patients with poor liver function. The adverse events may be induced by the drugs, or by the dead worms themselves. The Korea Institute of Drug Safety & Risk Management monitors drug-related adverse events in Korea, and its database included 256 probable or possible ADZ-associated events and 108 PZQT-associated events between 2006 and 2015. Such low incidence rates in Korea are due to the low single dose treatments of ADZ, and the short-term use of PZQT. The number of serious adverse events due to drug interaction induced by ADZ and PZQT were six and two, respectively. We conclude that ADZ and PZQT are generally safe drugs, but they must be used with caution in people with poor liver function or those being comedicated for gastroesophageal reflux disease.
참고문헌 (34)
- Albonico M, "Monitoring the efficacy of drugs for neglected tropical diseases controlled by preventive chemotherapy", J Global Antimicrob Resist, 3, pp.229~236 (2015)[DOI]
- "Update on the global status of the donation managed by WHO of the medicines for preventive chemotherapy (PC)"[URL]
- Verrest L, "Lack of clinical pharmacokinetic studies to optimize the treatment of neglected tropical diseases: a systematic review", Clin Pharmacokinet, 56, pp.583~606 (2017)[DOI]
- Dayan AD, "Albendazole, mebendazole and praziquatnel, Review of non-clinical toxicity and pharmacokinetics", Acta Trop, 86, pp.141~159 (2003)[DOI]
- Nagy J, "Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability", Am J Trop Med Hyg, 66, pp.260~263 (2002)[DOI]
- Pion SD, "The impact of two semiannual treatments with albendazole alone on lymphatic filariasis and soil-transmitted helminth infections: a community-based study in the Republic of Congo", Am J Trop Med Hyg, 92, pp.959~966 (2015)[DOI]
- Moser W, "Efficacy and safety of tribendimidine, tribendimidine plus ivermectin, tribendimidine plus oxantel pamoate, and albendazole plus oxantel pamoate against hookworm and concomitant soil-transmitted helminth infections in Tanzania and Cote d'Ivoire: a randomised, controlled, single- blinded, non-inferiority trial", Lancet Infect Dis, 17, pp.1162~1171 (2017)[DOI]
- Thomsen EK, "Efficacy, safety, and pharmacokinetics of coadministered diethylcarbamazine, albendazole, and ivermectin for treatment of bancroftian filariasis", Clin Infect Dis, 62, pp.334~341 (2016)[DOI]
- Moroni S, "Abdominal cystic echinococcosis treated with albendazole. A Pediatric Cohort Study", PLoS One, 11, pp.e0160472~ (2016)[DOI]
- Mohapatra S, "Drug-induced psychosis associated with albendazole-ivermectin combination therapy in a 10- year-old child", J Cjild Adolesc Psychopjarmacol, 25, pp.817~818 (2015)[DOI]
- Hogan J, "Hemolytic anemia and irreversible kidney and brain injuries after accidental intravenous injection of albendazole suspension in an infant", Clin Toxicol, 54, pp.72~73 (2016)[DOI]
- Tas A, "Loss of body hair as a side effect of albendazole", Wien Klin Wochenschr, 124, pp.220~ (2012)[DOI]
- 최기영, "Acute Drug-Induced Hepatitis Caused by Albendazole", Journal of Korean Medical Science, 23(5), pp.903~905 (2008), 대한의학회
- Marin Zuluaga JI, "Albendazole-induced granulomatous hepatitis: a case report", J Med Case Rep, 7, pp.201~ (2013)[DOI]
- Amoruso C, "Acute hepatitis as a side effect of albendazole: a pediatric case", Pediatr Med Chir, 31, pp.262~264 (2009)
- Opatrny L, "Death related to albendazole-induced pancytopenia: case report and review", Am J Trop Med Hyg, 72, pp.291~294 (2005)
- Borgsteede FH, "Doramectin and albendazole resistance in sheep in The Netherlands", Vet Parasitol, 144, pp.180~183 (2007)[DOI]
- Rashwan N, "Isothermal diagnostic assays for monitoring single nucleotide polymorphisms in Necator americanus associated with benzimidazole drug resistance", PLoS Negl Trop Dis, 10, pp.e0005113~ (2016)[DOI]
- Jaeger LH, "Status of benzimidazole resistance in intestinal nematode populations of livestock in Brazil: a systematic review", BMC Vet Res, 13, pp.358~ (2017)[DOI]
- Castro LS, "Albendazole as a promising molecule for tumor control", Redox Biol, 10, pp.90~99 (2016)[DOI]
- Kang BS, "Enhancing the in vitro anticancer activity of albendazole incorporated into chitosan- coated PLGA nanoparticles", Carbohydr Polym, 159, pp.39~47 (2017)[DOI]
- Movahedi F, "Nanoformulations of albendazole as effective anticancer and antiparasite agents", Nanomedicine (Lond), 12, pp.2555~2574 (2017)[DOI]
- Choi JS, "Foetal outcomes after exposure to albendazole in early pregnancy", J Obstet Gynaecol, 37, pp.1108~1111 (2017)[DOI]
- Salam RA, "Effect of administration of antihelminthics for soil-transmitted helminths during pregnancy", Cochrane Database Syst Rev (2015)
- Sun Q, "The cytotoxicity study of praziquantel enantiomers", Drug Des Devel Ther, 10, pp.2061~2068 (2016)[DOI]
- 채종일, "Praziquantel Treatment in Trematode and Cestode Infections: An Update", Infection and Chemotherapy, 45(1), pp.32~43 (2013), 대한감염학회[DOI]
- Kovac J, "In vitro and in vivo activity of R- and S- praziquantel enantiomers and the main human metabolite trans-4-hydroxy-praziquantel against Schistosoma haematobium", Parasit Vectors, 10, pp.365~ (2017)[DOI]
- Rim HJ, "The current pathobiology and chemotherapy of clonorchiasis", Kisaengchunghak Chapchi, 24(Suppl), pp.1~141 (1986)
- Zwang J, "Efficacy and safety of praziquantel 40 mg", kg in preschool-aged and school-aged children: a meta- analysis, 2017, pp.10, 47~
- Matthaiou DK, "Albendazole versus praziquantel in the treatment of neurocysticercosis: a meta-analysis of comparative trials", PLoS Negl Trop Dis, 2, pp.e194~ (2008)[DOI]
- Shen C, "A case of anaphylactic reaction to praziquantel treatment", Am J Trop Med Hyg, 76, pp.603~605 (2007)
- Jung-Min Lee, "Hypersensitive Reaction to Praziquantel in a Clonorchiasis Patient", Parasites, Hosts and Diseases, 49(3), pp.273~275 (2011), 대한기생충학ㆍ열대의학회
- Matsumoto J, "Adverse effects of praziquantel treatment of Schistosoma japonicum infection: involvement of host anaphylactic reactions induced by parasite antigen release", Int J Parasitol, 32, pp.461~471 (2002)[DOI]
- "Korea Institute of Drug Safety & Risk Management"[URL]